E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant. |
Cistite emorragica virus-associata dopo trapianto allogenico di cellule ematopoietiche |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation of the bladder caused by viral infection following bone marrow transplant. |
Infiammazione della vescica causata da infezione virale a seguito di trapianto di midollo osseo. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059348 |
E.1.2 | Term | Viral hemorrhagic cystitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059348 |
E.1.2 | Term | Viral hemorrhagic cystitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the time to resolution of macroscopic hematuria in recipients of Viralym-M (also known as ALVR-105) to that in patients receiving placebo. |
L’obiettivo primario è confrontare il tempo di risoluzione dell’ematuria macroscopica nei pazienti che ricevono Viralym-M (noto anche come ALVR-105) rispetto ai pazienti trattati con placebo. |
|
E.2.2 | Secondary objectives of the trial |
1) To compare the time to resolution of bladder pain as measured by Clinical Outcome Assessments (COAs) in recipients of Viralym-M to that in patients receiving placebo. 2) To assess number of days in the hospital. 3) To assess the incidence and severity of acute graft versus host disease (GVHD) and cytokine release syndrome (CRS) 4) To assess time to resolution of viremia for all target viruses. 5) To assess average daily bladder pain. |
1) Confrontare il tempo di risoluzione del dolore vescicale misurato mediante valutazioni degli esiti clinici (“ Clinical Outcome Assessments” COA) nei pazienti che ricevono Viralym-M rispetto a quello dei pazienti trattati con placebo. 2)Valutare il numero di giorni trascorsi in ospedale 3) Valutare l’incidenza e la gravità della malattia acuta da trapianto contro l’ospite (GVHD) e della sindrome da rilascio di citochine (SRC) 4) Valutare il tempo di risoluzione della viremia per tutti i virus target 4) Valutare il dolore vescicale medio giornaliero |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet all of the following criteria in order to be eligible to participate in the study: 1. Over 1 year of age at the time of informed consent/assent. 2. Had an allogeneic hematopoietic cell transplant (HCT) performed at least 21 days and not more than 1 year prior to randomization. 3. Myeloid engraftment confirmed. 4. Diagnosed with Hemorrhagic Cystitis. 5. At least 1 identified, suitably matched Viralym-M cell line for infusion is available. 6. Willing and able to provide written informed consent to participate in the study, or a parent or legal guardian is willing and able to provide written informed consent and the potential pediatric patient is able to provide assent in a manner approved by the Institutional Review Board/Independent Ethics Committee and local regulations. 7. Agree to use an effective contraceptive method during the study and for a minimum of 90 days after study treatment for all patients of childbearing potential. 8. A negative serum pregnancy test for female patients of childbearing potential |
Per essere idonei a partecipare allo studio i pazienti devono soddisfare tutti i seguenti criteri: 1. Oltre 1 anno di età al momento del consenso/assenso informato. 2. Precedente trapianto allogenico di cellule ematopoietiche (HCT) eseguito almeno 21 giorni e non più di 1 anno prima della randomizzazione. 3. Attecchimento mieloide confermato. 4. Diagnosi di Cistite Emorragica. 5. Disponibilità di almeno 1 linea cellulare identificata opportunamente compatibile per l’infusione di Viralym-M. 6. Disponibilità e capacità del paziente di fornire il consenso informato scritto per partecipare allo studio o disponibilità e capacità di un genitore o tutore legale di fornire il consenso informato scritto e capacità del potenziale paziente pediatrico di fornire l’assenso secondo modalità approvate dal Comitato Etico indipendente e dalle normative locali. 7. Consenso all’utilizzo di un metodo contraccettivo efficace durante lo studio e per un minimo di 90 giorni dopo il trattamento dello studio per tutte le pazienti potenzialmente fertili. 8. Test di gravidanza sul siero negativo per le pazienti potenzialmente fertili. |
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following criteria will be excluded from participation in the study:
1. Ongoing therapy with high-dose systemic corticosteroids. 2. Prior therapy with antithymocyte globulin, alemtuzumab (Campath1H), or other immunosuppressive T cell-targeted monoclonal antibodies within 28 days of randomization. 3. Evidence of active Grade >2 acute GVHD. 4. Presence of uncontrolled or progressive bacterial or fungal infections. 5. Presence of progressive, uncontrolled viral infections not targeted by Viralym-M. 6. Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder. 7. Known or presumed pneumonia secondary to any organism. 8. Donor lymphocyte infusion performed within 21 days prior to randomization. 9. Hemodynamic or respiratory instability. 10. Hemoglobin <7 g/dL despite RBC transfusions. 11. Evidence of active hepatic sinusoidal obstruction syndrome. 12. Liver dysfunction. 13. Renal dysfunction. 14. Evidence of encephalopathy. 15. Relapse of primary malignancy. 16. Receipt of other investigational antiviral treatments (eg, brincidofovir) within 28 days prior to randomization and throughout the duration of the study. 17. Pregnant or lactating or planning to become pregnant. |
I pazienti che soddisfano uno qualunque dei seguenti criteri saranno esclusi dalla partecipazione allo studio:
1. Terapia in corso con corticosteroidi sistemici ad alto dosaggio. 2. Precedente terapia con globulina anti-timociti, alemtuzumab (Campath-1H) o altri anticorpi monoclonali che hanno come bersaglio le cellule T immunosoppressive, entro 28 giorni dalla randomizzazione. 3. Evidenza di GVHD acuta di grado >2 in fase attiva. 4. Presenza di infezioni batteriche o micotiche non controllate o in fase progressiva. 5. Presenza di infezioni virali progressive e non controllate sulle quali non agisce Viralym-M. 6. Disturbo linfoproliferativo post-trapianto associato all’EBV non controllato o in fase progressiva 7. Polmonite secondaria, nota o presunta, a qualsiasi organismo. 8. Infusione di linfociti da donatore eseguita nei 21 giorni precedenti la randomizzazione. 9. Instabilità emodinamica o respiratoria 10. Emoglobina <7 g/dl nonostante le trasfusioni di RBC. 11. Evidenza di sindrome da ostruzione sinusoidale epatica attiva. 12. Disfunzione epatica. 13. Disfunzione renale. 14. Evidenza di encefalopatia. 15. Recidiva del tumore maligno primario. 16. Ricezione di altri trattamenti antivirali sperimentali (ad es. brincidofovir) nei 28 giorni precedenti la randomizzazione e per tutta la durata dello studio. 17. Gravidanza, allattamento o pianificazione di una gravidanza. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the time to resolution of macroscopic hematuria in patients with documented BK viruria. |
L’endpoint primario è il tempo di risoluzione dell’ematuria macroscopica nei pazienti con viruria di BK documentata. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Until the patient reaches the primary endpoint, the assessments will be performed daily up to Week 12. After Week 12, the assessments will be performed twice per week until Week 24. |
Fino a quando il paziente non raggiunge l'endpoint primario, le valutazioni saranno eseguite giornalmente fino alla settimana 12. Dopo la settimana 12, le valutazioni saranno eseguite due volte a settimana fino alla settimana 24. |
|
E.5.2 | Secondary end point(s) |
1) Time to resolution of bladder pain as measured by age-appropriate COAs. 2) Number of days in the hospital. 3) Time to resolution of viremia for all target viruses. 4) Average daily bladder pain. |
1) Tempo necessario per la risoluzione del dolore alla vescica, misurato in base agli esiti clinici (“ Clinical Outcome Assessments” COA) adeguati all'età. 2) Numero di giorni in ospedale. 3) Tempo necessario per la risoluzione della viremia per tutti i virus target. 4) Dolore vescicale giornaliero medio. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
For the 1st secondary end point – the assessments will be performed daily up to Week 12. After Week 12, the assessments will be performed weekly until Week 24. For 2nd and 3rd secondary end points - Week 24. For 4th secondary end point - Week 6. |
Per il 1 ° endpoint secondario: le valutazioni verranno eseguite giornalmente fino alla settimana 12. Dopo la settimana 12, le valutazioni verranno eseguite settimanalmente fino alla settimana 24. Per il 2 ° e il 3 ° punto secondario - Settimana 24. Per il 4 ° endpoint secondario - Settimana 6. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 32 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Japan |
Korea, Republic of |
United States |
France |
Germany |
Italy |
Sweden |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last subject (LVLS) |
LVLS |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |